MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...

BCVA improved +8.9 letters versus +3.2 letters for aflibercept control compared to baseline. CST improved 68.1 microns versus 30.5 microns for aflibercept control compared to baseline. Visual and ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

The study comprised 161 patients split between three arms: EYP-1901 2mg (low dose; n=53); EYP-1901 3mg (high dose, n=54); and the standard of care, which was aflibercept 2mg every eight weeks (n=54).

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

Once a subject is enrolled in the study, they receive two loading doses of aflibercept (2 mg), one at Week -8 and another at Week -4. Subjects who achieve pre-defined visual acuity measures are ...

DURAVYU 2.7mg demonstrated an early, sustained, and clinically meaningful improvement in best-corrected visual acuity (BCVA) and anatomical control versus the aflibercept control arm. A favorable ...